Annovis Bio, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
Phone 484-875-3192
Fiscal Year End 1231
EIN 262540421
Financial Overview
FY2025
-$24.59M
Net Income
$21.08M
Total Assets
$4.62M
Total Liabilities
$10.55M
Cash & Equivalents
$-1.40
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
| 4/A Insider transaction amendment | November 25, 2025 | View on SEC |
| 4 Insider stock transaction report | November 25, 2025 | View on SEC |
| 4 Insider stock transaction report | November 21, 2025 | View on SEC |
| 4 Insider stock transaction report | November 18, 2025 | View on SEC |
Annual Reports
10-K March 13, 2026
- Successfully completed Phase 2/3 clinical trial for ANVS401 in early Alzheimer's disease with promising preliminary data.
- ANVS401's unique mechanism aims to prevent neurotoxic protein formation, differentiating it in the neurodegenerative disease market.
Insider Trading
STRONG BUY 1 insiders
12 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.